CRISPR Therapeutics - CRSP Stock Forecast, Price & News

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last year. There are currently 1 sell rating, 6 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CRSP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRSP, but not buy additional shares or sell existing shares.
View CRSP analyst ratings or view top-rated stocks.

15 brokerages have issued 1-year price targets for CRISPR Therapeutics' shares. Their CRSP share price forecasts range from $37.00 to $220.00. On average, they expect the company's stock price to reach $101.44 in the next twelve months. This suggests a possible upside of 101.1% from the stock's current price.
View analysts price targets for CRSP or view top-rated stocks among Wall Street analysts.

CRISPR Therapeutics' stock was trading at $75.78 at the beginning of 2022. Since then, CRSP shares have decreased by 33.4% and is now trading at $50.45.
View the best growth stocks for 2022 here.

CRISPR Therapeutics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 11,640,000 shares, a decrease of 7.3% from the October 31st total of 12,550,000 shares. Based on an average daily trading volume, of 1,080,000 shares, the days-to-cover ratio is currently 10.8 days. Approximately 15.5% of the shares of the stock are sold short.
View CRISPR Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 21st 2023.
View our CRSP earnings forecast.

CRISPR Therapeutics AG (NASDAQ:CRSP) released its earnings results on Tuesday, November, 1st. The company reported ($2.24) earnings per share for the quarter, beating the consensus estimate of ($2.30) by $0.06. The firm earned $0.09 million during the quarter, compared to the consensus estimate of $3.53 million. CRISPR Therapeutics had a negative trailing twelve-month return on equity of 31.34% and a negative net margin of 4,831.79%.

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

(CRSP) raised $75 million in an initial public offering on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

CRISPR Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (5.46%), BlackRock Inc. (3.00%), State Street Corp (2.00%), Vanguard Group Inc. (1.83%), Price T Rowe Associates Inc. MD (1.52%) and Bellevue Group AG (1.19%). Insiders that own company stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni, Tony W Ho and Tony W Ho.
View institutional ownership trends.

Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRSP stock can currently be purchased for approximately $50.45.

CRISPR Therapeutics (NASDAQ:CRSP) has a market capitalization of $3.95 billion and generates $914.96 million in revenue each year. The company earns $377.66 million in net income (profit) each year or ($8.80) on an earnings per share basis.

The company employs 473 workers across the globe.

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The official website for the company is www.crisprtx.com. The company can be reached via phone at (141) 561-3277 or via email at susan.kim@crisprtx.com.